Target intelligence / Profile preview

STAT3 messenger RNA (STAT3)

Target
STAT3
Molecular classification
Transcription factor (for the protein product, not mRNA), mRNA transcript (natural RNA), Other
01

Overview

"STAT3 messenger RNA" is the single-stranded RNA transcript synthesized from the STAT3 gene, which encodes the STAT3 protein—a member of the STAT family of transcription factors. The mRNA is a natural molecule in cells and is not itself a canonical therapeutic target; rather, the encoded STAT3 protein is the drug target in most disease settings. The STAT3 mRNA can be regulated at the level of localization, stability, splicing, and translation, with emerging research indicating that post-transcriptional regulation (for example, by RNA-binding proteins like FMRP) can affect cellular processes relevant to cancer metastasis[1]. Therapeutic targeting of STAT3 mRNA by RNA interference or antisense oligonucleotides is an experimental approach in early-stage research. However, the term "STAT3 messenger RNA" is not the standard or canonical name for a therapeutic target: the actual drug target is the "Signal transducer and activator of transcription 3" protein. The mRNA itself should only be considered a target in the context of RNA-targeted therapies.

Other names
STAT3 mRNASTAT3 transcriptSTAT3 messenger RNA
02

Mechanism of action

For antisense oligonucleotides or siRNA: bind and degrade STAT3 mRNA to prevent translation of STAT3 protein. Small-molecule inhibitors do not target the mRNA.

03

Biological functions

Encodes STAT3, a critical regulator of signal transductionmRNA localization and translation regulation in some cancer contexts[1]
04

Disease associations

Cancer (by way of coding for STAT3, which is an oncogenic protein)[2][3]Inflammation (role via protein)[2]Immune disorders (role via protein)[2][3]Infection (role via protein)[2]
05

Safety considerations

Targeting mRNA may result in off-target gene silencing, immune activation, or toxicitySpecific safety concerns depend on the modality (antisense, siRNA, etc.), and are being investigated in preclinical and early clinical studies only
06

Interacting drugs

None directly; drugs target the STAT3 protein, not its mRNA (e.g., niclosamide, napabucasin inhibit STAT3 protein activity)[2]

1 more in the full profile.

07

Biomarkers

STAT3 mRNA expression levels may serve as surrogate markers for STAT3 pathway activation in certain disease contexts, mostly in research use

Beyond the preview

Go deeper on STAT3 messenger RNA (STAT3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on STAT3 messenger RNA (STAT3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call